Fat Redistribution During Tesamorelin Therapy
During tesamorelin therapy, fat redistributes away from visceral (intra-abdominal) compartments and trunk regions, with significant reductions in visceral adipose tissue, trunk fat, and hepatic fat, while subcutaneous adipose tissue and limb fat remain largely preserved or show minimal reduction.
Pattern of Fat Redistribution
Tesamorelin demonstrates a selective reduction in metabolically harmful fat depots while sparing peripheral subcutaneous fat:
Visceral Fat Reduction
- Visceral adipose tissue (VAT) decreases by approximately 15-18% over 6-12 months of treatment 1, 2, 3
- Absolute reductions range from 21-35 cm² in cross-sectional area 2, 3
- This reduction is sustained with continued therapy but rapidly reverses upon discontinuation 2
Trunk and Central Fat Loss
- Trunk fat decreases significantly (mean reduction of 1.18 kg) 1
- Waist circumference reduces by 1.6-3.4 cm 1, 3
- Waist-to-hip ratio improves 4
- Hepatic fat decreases substantially (median reduction of 2-4.2% in lipid-to-water percentage) 5, 1
Preserved Subcutaneous Fat
- Abdominal subcutaneous adipose tissue shows no significant change 3
- Limb fat shows minimal reduction (0.22 kg decrease) but this is far less pronounced than visceral changes 1
- This preservation is clinically important, as subcutaneous fat serves protective metabolic functions 6, 7
Clinical Significance of This Redistribution Pattern
The selective targeting of visceral over subcutaneous fat is metabolically favorable because:
- Visceral adiposity is strongly associated with insulin resistance, metabolic syndrome, cardiovascular disease, and hepatic steatosis 7, 8
- Subcutaneous fat, particularly in peripheral locations, has protective metabolic effects 9
- The reduction in trunk-to-appendicular fat ratio improves overall metabolic profile 4
Additional Body Composition Changes
- Lean body mass increases by 1.42 kg 1, representing a favorable shift in body composition
- No significant change in BMI despite improvements in fat distribution 1
Important Caveats
The fat redistribution is treatment-dependent: When tesamorelin is discontinued, VAT reductions are rapidly lost, with patients returning toward baseline within weeks 2. This necessitates continuous therapy to maintain benefits.
The mechanism differs fundamentally from thiazolidinediones, which increase subcutaneous fat while decreasing visceral fat 6, whereas tesamorelin reduces total fat mass but does so preferentially from visceral depots.
Dorsocervical fat (buffalo hump): Post hoc analysis demonstrates that tesamorelin reduces VAT equally effectively in patients with or without dorsocervical fat accumulation 10, though the direct effect on dorsocervical fat itself was not specifically quantified in these studies.